1.Mechanisms of Core Compound Formula and Compatibility of Traditional Chinese Medicine Components for Prevention and Treatment of Chronic Atrophic Gastritis Based on Huazhuo Jiedu Therapy
Fan GAO ; Xiaoxuan MO ; Fengyue XU ; Jiaye TIAN ; Xinmeng ZHAO ; Jianming JIANG ; Qiuhong GUO
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):51-64
ObjectiveTo reveal the compatibility rules of the core compound formula and traditional Chinese medicine (TCM) components for prevention and treatment of chronic atrophic gastritis (CAG) by Huazhuo Jiedu (turbidity-resolving and detoxifying) therapy through uniform design in view of the potential regulatory pathway of endogenous turbid-toxin retention in CAG, elucidate the potential pathway by which the compound formulas regulate the Wnt/β-catenin-connexin 43 (CX43) signaling axis, demonstrated the efficacy enhancement and toxicity attenuation among the components, thus providing experimental evidence for the scientific application of multi-component, multi-target compatibility in TCM compound formulas. MethodsA mouse model of CAG was established with N-methyl-N-nitrosourea (MNU). Sixty mice were randomly allocated into 5 groups (n=12 per group): blank control, model, low-dose Huazhuo Jiedu core compound formula (HXFF-L, 4.004 g·kg-1), high-dose Huazhuo Jiedu core compound formula (HXFF-H, 8.008 g·kg-1), and positive control (folic acid at 11 mg·kg-1 + vitamin B12 at 14 mg·kg-1). The therapeutic efficacy and molecular mechanism of the core compound formula were evaluated by hematoxylin-eosin (HE) staining, Alcian blue-periodic acid-Schiff (AB-PAS) staining, enzyme-linked immunosorbent assay (ELISA), transmission electron microscopy (TEM), immunofluorescence assay, and Western blot. The chemical components of the core compound formula were detected and effective components were screened by ultra-high performance liquid chromatography coupled with quadrupole-orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS). Another 120 mice were randomized into blank control, model, and 8 HXFF component-combination groups with different dosages (uniform design groups 1-8, n=12 per group). A uniform design was adopted, with pathological scores of mouse gastric tissue as well as serum levels of pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), and gastrin 17 (GAS17) set as dependent variables. Multivariate linear regression analysis was performed to predict the optimal proportion of core components in the compound formula and explore its compatibility rules. ResultsPharmacodynamic validation showed that compared with the blank control group, the model group had decreased gastric weight index (P<0.01) and increased pathological damage score and inflammatory factor levels (P<0.01). Compared with the model group, these indicators were reversed in the HXFF-L, HXFF-H, and positive control groups (P<0.05, P<0.01). Immunofluorescence results showed that CX43 expression was downregulated in the model group compared with the blank control group (P<0.01) and upregulated in the HXFF-H and positive control groups compared with the model group (P<0.05, P<0.01). Western blot results showed that compared with the blank control group, the model group demonstrated upregulated protein levels of Wnt and β-catenin in the gastric tissue (P<0.01). Compared with those in the model group, the protein level of Wnt was downregulated in the HXFF-L, HXFF-H, and positive control groups (P<0.05, P<0.01), while that of β-catenin was downregulated only in the HXFF-H group (P<0.05). A total of 25 compounds were identified in the core compound formula, including 9 from Coptidis Rhizoma, 10 from Pogostemonis Herba, 2 from Scorpio, and 4 from Lilii Bulbus. According to the category and origin of compounds, Coptidis Rhizoma alkaloids, Pogostemonis Herba volatile oils, Scorpio peptides, and Lilii Bulbus alkaloids were finally selected for component research. The predicted optimal combination of TCM components was as follows: Coptidis Rhizoma alkaloids at 75 mg·kg-1, Pogostemonis Herba volatile oils at 2.25 mg·kg-1, Scorpio protein extract at 90 mg·kg-1, and Lilii Bulbus alkaloids at 9 mg·kg-1. Coptidis Rhizoma alkaloids, Scorpio protein extract, Pogostemonis Herba volatile oils, and Lilii Bulbus alkaloids can ameliorate pathological lesions of the gastric tissue. Scorpio protein extract exerted positive regulatory effects on the gastric function, while Pogostemonis Herba volatile oils and Lilii Bulbus alkaloids showed negative correlations with partial gastric function indicators. Further investigations are required to clarify their dose-effect relationships and safety profiles. ConclusionThis study, for the first time, predicts the optimal proportion and synergistic regulatory mechanism of the core compound formula of Huazhuo Jiedu therapy, revealing the synergistic compatibility logic of its components. It provides a novel strategy for the precise TCM treatment of CAG and the modern development of compound formulas.
2.Mechanisms of Core Compound Formula and Compatibility of Traditional Chinese Medicine Components for Prevention and Treatment of Chronic Atrophic Gastritis Based on Huazhuo Jiedu Therapy
Fan GAO ; Xiaoxuan MO ; Fengyue XU ; Jiaye TIAN ; Xinmeng ZHAO ; Jianming JIANG ; Qiuhong GUO
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(21):51-64
ObjectiveTo reveal the compatibility rules of the core compound formula and traditional Chinese medicine (TCM) components for prevention and treatment of chronic atrophic gastritis (CAG) by Huazhuo Jiedu (turbidity-resolving and detoxifying) therapy through uniform design in view of the potential regulatory pathway of endogenous turbid-toxin retention in CAG, elucidate the potential pathway by which the compound formulas regulate the Wnt/β-catenin-connexin 43 (CX43) signaling axis, demonstrated the efficacy enhancement and toxicity attenuation among the components, thus providing experimental evidence for the scientific application of multi-component, multi-target compatibility in TCM compound formulas. MethodsA mouse model of CAG was established with N-methyl-N-nitrosourea (MNU). Sixty mice were randomly allocated into 5 groups (n=12 per group): blank control, model, low-dose Huazhuo Jiedu core compound formula (HXFF-L, 4.004 g·kg-1), high-dose Huazhuo Jiedu core compound formula (HXFF-H, 8.008 g·kg-1), and positive control (folic acid at 11 mg·kg-1 + vitamin B12 at 14 mg·kg-1). The therapeutic efficacy and molecular mechanism of the core compound formula were evaluated by hematoxylin-eosin (HE) staining, Alcian blue-periodic acid-Schiff (AB-PAS) staining, enzyme-linked immunosorbent assay (ELISA), transmission electron microscopy (TEM), immunofluorescence assay, and Western blot. The chemical components of the core compound formula were detected and effective components were screened by ultra-high performance liquid chromatography coupled with quadrupole-orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS). Another 120 mice were randomized into blank control, model, and 8 HXFF component-combination groups with different dosages (uniform design groups 1-8, n=12 per group). A uniform design was adopted, with pathological scores of mouse gastric tissue as well as serum levels of pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), and gastrin 17 (GAS17) set as dependent variables. Multivariate linear regression analysis was performed to predict the optimal proportion of core components in the compound formula and explore its compatibility rules. ResultsPharmacodynamic validation showed that compared with the blank control group, the model group had decreased gastric weight index (P<0.01) and increased pathological damage score and inflammatory factor levels (P<0.01). Compared with the model group, these indicators were reversed in the HXFF-L, HXFF-H, and positive control groups (P<0.05, P<0.01). Immunofluorescence results showed that CX43 expression was downregulated in the model group compared with the blank control group (P<0.01) and upregulated in the HXFF-H and positive control groups compared with the model group (P<0.05, P<0.01). Western blot results showed that compared with the blank control group, the model group demonstrated upregulated protein levels of Wnt and β-catenin in the gastric tissue (P<0.01). Compared with those in the model group, the protein level of Wnt was downregulated in the HXFF-L, HXFF-H, and positive control groups (P<0.05, P<0.01), while that of β-catenin was downregulated only in the HXFF-H group (P<0.05). A total of 25 compounds were identified in the core compound formula, including 9 from Coptidis Rhizoma, 10 from Pogostemonis Herba, 2 from Scorpio, and 4 from Lilii Bulbus. According to the category and origin of compounds, Coptidis Rhizoma alkaloids, Pogostemonis Herba volatile oils, Scorpio peptides, and Lilii Bulbus alkaloids were finally selected for component research. The predicted optimal combination of TCM components was as follows: Coptidis Rhizoma alkaloids at 75 mg·kg-1, Pogostemonis Herba volatile oils at 2.25 mg·kg-1, Scorpio protein extract at 90 mg·kg-1, and Lilii Bulbus alkaloids at 9 mg·kg-1. Coptidis Rhizoma alkaloids, Scorpio protein extract, Pogostemonis Herba volatile oils, and Lilii Bulbus alkaloids can ameliorate pathological lesions of the gastric tissue. Scorpio protein extract exerted positive regulatory effects on the gastric function, while Pogostemonis Herba volatile oils and Lilii Bulbus alkaloids showed negative correlations with partial gastric function indicators. Further investigations are required to clarify their dose-effect relationships and safety profiles. ConclusionThis study, for the first time, predicts the optimal proportion and synergistic regulatory mechanism of the core compound formula of Huazhuo Jiedu therapy, revealing the synergistic compatibility logic of its components. It provides a novel strategy for the precise TCM treatment of CAG and the modern development of compound formulas.
3.Clinical value of a deep learning multi-view fusion model for diagnosing fetal conotruncal defects
Hongmei GUO ; Zhengxi DENG ; Qiuhong XU ; Sha WAN ; Jianhua LUO ; Shuangli REN ; Shuxing ZHONG ; Ting LEI ; Xiaoyan MA ; Yafui YAN
Chinese Journal of Perinatal Medicine 2025;28(10):842-849
Objective:To develop an ultrasound multi-view fusion recognition model and evaluate its clinical value in diagnosing fetal conotruncal defects (CTD).Methods:This prospective study collected cardiac ultrasound images from fetuses at 20-32 weeks of gestation undergoing prenatal ultrasound at Dongguan Maternal and Child Health Hospital between September 2022 and May 2024. The case group comprised fetuses diagnosed with CTD, while controls with normal cardiac structures were collected at a 1∶2 ratio. Both groups were divided into modeling training and validation sets at a 3∶1 ratio. One optimal standard image each from the four-chamber view, left ventricular outflow tract view, right ventricular outflow tract view, and three vessels and trachea view was included per fetus. A deep learning-based multi-view fusion recognition model was developed to differentiate normal conotruncal anatomy from CTD. Model performance was validated against post-abortion pathology or postnatal echocardiography results. SAS software was used for statistical analysis to calculate the sensitivity and specificity of three fusion models (based on positivity in any two, three, or four views, and were designated as Fusion Model 1, Fusion Model 2, and Fusion Model 3, respectively), with the optimal model determined by the maximum Youden index. Senior, intermediate, and junior prenatal sonologists independently diagnosed cases in the validation set under blinding conditions. Their diagnostic results were compared with those of the optimal model. Paired Chi-square test (Cochran's Q test) was employed to compare the differences between the diagnostic accuracy rates of sonologists at different experience levels and the sensitivity of the optimal model, thereby analyzing the auxiliary diagnostic value of the multi-view fusion recognition model. Results:The study included 88 CTD cases, excluding six cases (non-CTD diagnosed by post-abortion pathology or postnatal echocardiography or poor image quality), divided into 60 training and 22 validation cases (12 tetralogy of Fallot, four double outlet right ventricle, three transposition of great arteries, three persistent truncus arteriosus). The control group included 176 cases, excluding 15 cases (other cardiac abnormalities confirmed postnatally or poor image quality after re-evaluation), divided into 120 training and 41 validation cases. The sensitivities of Fusion Model 1, Fusion Model 2, and Fusion Mudel 3 were 0.86, 0.64, and 0.27, while their specificities were 0.76, 0.95, and 1.00, respectively. Fusion Model 1 demonstrated the highest Youden index (0.62) and was selected as optimal. Its diagnostic sensitivity showed no significant difference from senior sonologists [86% vs. 91% (20/22), Bonferroni-corrected P>0.999], but was significantly higher than intermediate [55% (12/22), Bonferroni-corrected P=0.049] and junior sonologists [32% (7/22), Bonferroni-corrected P=0.003]. Conclusion:The deep learning multi-view fusion model achieved diagnostic performance comparable to senior sonologists, demonstrating potential value in assisting CTD diagnosis, training less experienced sonologists, and supporting research and education.
4.Clinical manifestations of medically refractory hereditary movement disorders in children and efficacy of deep brain stimulation
Lifang DAI ; Tinghong LIU ; Feng ZHAI ; Anna ZHOU ; Qiuhong WANG ; Zihang XIE ; Xiaojuan TIAN ; Xu WANG ; Shuli LIANG ; Hui XIONG ; Changhong DING
Chinese Journal of Applied Clinical Pediatrics 2025;40(7):526-532
Objective:To investigate the clinical manifestations of medically refractory hereditary movement disorders in children and the efficacy of deep brain stimulation (DBS).Methods:A case series study.The clinical and follow-up data of 20 children with medically refractory hereditary movement disorders who underwent DBS treatment at the Neurology and Functional Neurosurgery Departments of Beijing Children′s Hospital, Capital Medical University, from July 2018 to April 2024, were retrospectively analyzed.The severity of movement disorder symptoms and surgical effects were evaluated using the Burke-Fahn-Marsden Dystonia Rating Scale Movement(BFMDRS-M) or the Unified Parkinson′s Disease Rating Scale Ⅲ(UPDRS Ⅲ).Results:There were 12 males and 8 females among the 20 children, with an onset age ranging from 4 months to 12 years and 5 months.Fourteen patients had hereditary dystonia, which is related to KMT2B in 11 patients, TOR1A in 2 patients and SGCE in 1 patient.Two patients had choreoathetosis, which is related to ADCY5-related familial movement disorders.Two patients had early-onset Parkinson′s disease, which is related to ATP6AP2 in 1 patient and VPS13C in 1 patient.Two patients had neurodevelopmental disorders with involuntary movements, which is related to GNAO1 in 1 patient, and the other patient was idiopathic.All the children were given oral Levodopa, Benzhexol, Baclofen, Tiapride Hydrochloride, Clonazepam alone or in combination.Three children showed obvious dyskinesia after Levodopa treatment.The symptoms of movement disorders in all children exhibited little to no improvement.Levetiracetam and Zonisamide had unstable effects in the treatment of myoclonia.DBS surgery was performed on all the patients aged from 3 to 16 years.Electrodes were successfully inserted into bilateral globus pallidus internus in 14 cases and bilateral subthalamic nuclei in 4 cases.The target was unknown in 2 cases.No surgery-related complications were observed.The patients were followed up for 3 months to 6 years, and the last follow-up age of the patients ranged from 5 years and 7 months to 22 years and 1 month.The rate of improvement in BFMDRS-M score was 37%-100% in 16 patients and >70% in 7 patients with hereditary dystonia.The rate of improvement in UPDRS Ⅲ score was 23% in 1 patient with VPS13C-related early-onset Parkinson′s disease. Conclusions:Childhood medically refractory hereditary movement disorders are a case series that exhibits significant phenotypic and genotypic heterogeneity.DBS surgery demonstrates significant efficacy for KMT2B-, TOR1A-, and SGCE-related hereditary movement disorders.
5.Clinical manifestations of medically refractory hereditary movement disorders in children and efficacy of deep brain stimulation
Lifang DAI ; Tinghong LIU ; Feng ZHAI ; Anna ZHOU ; Qiuhong WANG ; Zihang XIE ; Xiaojuan TIAN ; Xu WANG ; Shuli LIANG ; Hui XIONG ; Changhong DING
Chinese Journal of Applied Clinical Pediatrics 2025;40(7):526-532
Objective:To investigate the clinical manifestations of medically refractory hereditary movement disorders in children and the efficacy of deep brain stimulation (DBS).Methods:A case series study.The clinical and follow-up data of 20 children with medically refractory hereditary movement disorders who underwent DBS treatment at the Neurology and Functional Neurosurgery Departments of Beijing Children′s Hospital, Capital Medical University, from July 2018 to April 2024, were retrospectively analyzed.The severity of movement disorder symptoms and surgical effects were evaluated using the Burke-Fahn-Marsden Dystonia Rating Scale Movement(BFMDRS-M) or the Unified Parkinson′s Disease Rating Scale Ⅲ(UPDRS Ⅲ).Results:There were 12 males and 8 females among the 20 children, with an onset age ranging from 4 months to 12 years and 5 months.Fourteen patients had hereditary dystonia, which is related to KMT2B in 11 patients, TOR1A in 2 patients and SGCE in 1 patient.Two patients had choreoathetosis, which is related to ADCY5-related familial movement disorders.Two patients had early-onset Parkinson′s disease, which is related to ATP6AP2 in 1 patient and VPS13C in 1 patient.Two patients had neurodevelopmental disorders with involuntary movements, which is related to GNAO1 in 1 patient, and the other patient was idiopathic.All the children were given oral Levodopa, Benzhexol, Baclofen, Tiapride Hydrochloride, Clonazepam alone or in combination.Three children showed obvious dyskinesia after Levodopa treatment.The symptoms of movement disorders in all children exhibited little to no improvement.Levetiracetam and Zonisamide had unstable effects in the treatment of myoclonia.DBS surgery was performed on all the patients aged from 3 to 16 years.Electrodes were successfully inserted into bilateral globus pallidus internus in 14 cases and bilateral subthalamic nuclei in 4 cases.The target was unknown in 2 cases.No surgery-related complications were observed.The patients were followed up for 3 months to 6 years, and the last follow-up age of the patients ranged from 5 years and 7 months to 22 years and 1 month.The rate of improvement in BFMDRS-M score was 37%-100% in 16 patients and >70% in 7 patients with hereditary dystonia.The rate of improvement in UPDRS Ⅲ score was 23% in 1 patient with VPS13C-related early-onset Parkinson′s disease. Conclusions:Childhood medically refractory hereditary movement disorders are a case series that exhibits significant phenotypic and genotypic heterogeneity.DBS surgery demonstrates significant efficacy for KMT2B-, TOR1A-, and SGCE-related hereditary movement disorders.
6.Clinical value of a deep learning multi-view fusion model for diagnosing fetal conotruncal defects
Hongmei GUO ; Zhengxi DENG ; Qiuhong XU ; Sha WAN ; Jianhua LUO ; Shuangli REN ; Shuxing ZHONG ; Ting LEI ; Xiaoyan MA ; Yafui YAN
Chinese Journal of Perinatal Medicine 2025;28(10):842-849
Objective:To develop an ultrasound multi-view fusion recognition model and evaluate its clinical value in diagnosing fetal conotruncal defects (CTD).Methods:This prospective study collected cardiac ultrasound images from fetuses at 20-32 weeks of gestation undergoing prenatal ultrasound at Dongguan Maternal and Child Health Hospital between September 2022 and May 2024. The case group comprised fetuses diagnosed with CTD, while controls with normal cardiac structures were collected at a 1∶2 ratio. Both groups were divided into modeling training and validation sets at a 3∶1 ratio. One optimal standard image each from the four-chamber view, left ventricular outflow tract view, right ventricular outflow tract view, and three vessels and trachea view was included per fetus. A deep learning-based multi-view fusion recognition model was developed to differentiate normal conotruncal anatomy from CTD. Model performance was validated against post-abortion pathology or postnatal echocardiography results. SAS software was used for statistical analysis to calculate the sensitivity and specificity of three fusion models (based on positivity in any two, three, or four views, and were designated as Fusion Model 1, Fusion Model 2, and Fusion Model 3, respectively), with the optimal model determined by the maximum Youden index. Senior, intermediate, and junior prenatal sonologists independently diagnosed cases in the validation set under blinding conditions. Their diagnostic results were compared with those of the optimal model. Paired Chi-square test (Cochran's Q test) was employed to compare the differences between the diagnostic accuracy rates of sonologists at different experience levels and the sensitivity of the optimal model, thereby analyzing the auxiliary diagnostic value of the multi-view fusion recognition model. Results:The study included 88 CTD cases, excluding six cases (non-CTD diagnosed by post-abortion pathology or postnatal echocardiography or poor image quality), divided into 60 training and 22 validation cases (12 tetralogy of Fallot, four double outlet right ventricle, three transposition of great arteries, three persistent truncus arteriosus). The control group included 176 cases, excluding 15 cases (other cardiac abnormalities confirmed postnatally or poor image quality after re-evaluation), divided into 120 training and 41 validation cases. The sensitivities of Fusion Model 1, Fusion Model 2, and Fusion Mudel 3 were 0.86, 0.64, and 0.27, while their specificities were 0.76, 0.95, and 1.00, respectively. Fusion Model 1 demonstrated the highest Youden index (0.62) and was selected as optimal. Its diagnostic sensitivity showed no significant difference from senior sonologists [86% vs. 91% (20/22), Bonferroni-corrected P>0.999], but was significantly higher than intermediate [55% (12/22), Bonferroni-corrected P=0.049] and junior sonologists [32% (7/22), Bonferroni-corrected P=0.003]. Conclusion:The deep learning multi-view fusion model achieved diagnostic performance comparable to senior sonologists, demonstrating potential value in assisting CTD diagnosis, training less experienced sonologists, and supporting research and education.
7.Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance
Xianlong WANG ; Chuan ZHAO ; Jincheng LIN ; Hongxing LIU ; Qiuhong ZENG ; Huadong CHEN ; Ye WANG ; Dapeng XU ; Wen CHEN ; Moping XU ; En ZHANG ; Da LIN ; Zhixiong LIN
Chinese Medical Journal 2024;137(7):859-870
Background::Adamantinomatous craniopharyngioma (ACP) is the commonest pediatric sellar tumor. No effective drug is available and interpatient heterogeneity is prominent. This study aimed to identify distinct molecular subgroups of ACP based on the multi-omics profiles, imaging findings, and histological features, in order to predict the response to anti-inflammatory treatment and immunotherapies.Methods::Totally 142 Chinese cases diagnosed with craniopharyngiomas were profiled, including 119 ACPs and 23 papillary craniopharyngiomas. Whole-exome sequencing (151 tumors, including recurrent ones), RNA sequencing (84 tumors), and DNA methylome profiling (95 tumors) were performed. Consensus clustering and non-negative matrix factorization were used for subgrouping, and Cox regression were utilized for prognostic evaluation, respectively.Results::Three distinct molecular subgroups were identified: WNT, ImA, and ImB. The WNT subgroup showed higher Wnt/β-catenin pathway activity, with a greater number of epithelial cells and more predominantly solid tumors. The ImA and ImB subgroups had activated inflammatory and interferon response pathways, with enhanced immune cell infiltration and more predominantly cystic tumors. Mitogen-activated protein kinases (MEK/MAPK) signaling was activated only in ImA samples, while IL-6 and epithelial-mesenchymal transition biomarkers were highly expressed in the ImB group, mostly consisting of children. The degree of astrogliosis was significantly elevated in the ImA group, with severe finger-like protrusions at the invasive front of the tumor. The molecular subgrouping was an independent prognostic factor, with the WNT group having longer event-free survival than ImB (Cox, P = 0.04). ImA/ImB cases were more likely to respond to immune checkpoint blockade (ICB) therapy than the WNT group ( P <0.01). In the preliminary screening of subtyping markers, CD38 was significantly downregulated in WNT compared with ImA and ImB ( P = 0.01). Conclusions::ACP comprises three molecular subtypes with distinct imaging and histological features. The prognosis of the WNT type is better than that of the ImB group, which is more likely to benefit from the ICB treatment.
8.Clinical characteristics of 16 patients with nucleotide excision repair disorders and literature review
Lizhu HU ; Jing WANG ; Qiuhong WANG ; Zhou YANG ; Yu HUANG ; Jing GAO ; Jian CHEN ; Bin WANG ; Rui LIU ; Xian XU ; Nan PENG ; Hui WANG ; Yujiao DENG ; Liqiang WANG ; Haixu CHEN ; Lin MA ; Liping ZOU
Chinese Journal of Applied Clinical Pediatrics 2022;37(22):1730-1735
Objective:To summarize the clinical manifestations and gene mutation features of patients with nucleotide excision repair (NER) disorders.Methods:A retrospective analysis was made on clinical data of patients with NER disorders who were admitted to the Chinese People′s Liberation Army General Hospital from October 2008 to February 2022 and diagnosed in the Outpatient Department of Beijing Children′s Hospital, Capital Medical University from October 2015 to February 2022.Literature on previously reported Chinese patients with NER disorders was reviewed.Results:(1)A total of 16 patients with NER disorders were enrolled, including 6 males and 10 females.The onset age was 7.5 (4.0, 12.0) months and the age at diagnosis was 42.0 (21.5, 77.0) months.There were 3 types of NER disorders: Cockayne syndrome (CS) in 13 cases, Xeroderma Pigmentosum (XP) in 2 cases and Cerebro-Oculo-Facio-Skeletal syndrome (COFS) in 1 case.Four disease-causing genes were detected: CSA gene in 11 cases, CSB gene in 3 cases, XPG gene in 1 case, and XPD gene in 1 case.The first symptoms of the 16 patients were photosensitivity and developmental delay, and neurological symptoms were observed in all the 3 NER disorder types.XP and CS patients had skin symptoms.CS patients presented typical facial features, visual and auditory impairment, microcephaly and changes in neuroimaging features.COFS patients showed intrauterine growth retardation.(2)Results of literature review: a total of 96 Chinese patients reported were retrieved, involving 6 disease types, including CS in 45 cases, XP in 44 cases, trichothiodystrophy in 4 cases, COFS in 1 case, XP-CS in 1 case, and ultraviolet sensitive syndrome in 1 case.Nine mutated genes were identified: CSA in 33 cases, XPA in 15 cases, CSB in 13 cases, XPV in 10 cases, XPC in 9 cases, XPG in 7 cases, XPD in 7 cases, XPF in 1 case, and MPLKIP in 1 case.The common symptoms were growth failure (62 cases), skin photosensitivity (61 cases), typical facial features (52 cases), mental retardation (49 cases) and microcephaly (48 cases). Among 36 cases had imaging data 33 cases(91.7%)had calcification of basal nucleus or globus pallidus.Three cases had intrauterine growth retardation and microcephaly during pregnancy. Conclusions:Patients with such prenatal manifestations as intrauterine growth retardation and microcephaly or with typical symptoms like skin photosensitivity, typical facial features, growth failure, mental retardation, hypertonia, and calcifications of basal ganglia should be suspected of NER disorders.Early genetic testing is recommended to confirm the diagnosis.
9.Construction and verification of an intelligent measurement model for diabetic foot ulcer.
Nan ZHAO ; Qiuhong ZHOU ; Jianzhong HU ; Weihong HUANG ; Jingcan XU ; Min QI ; Min PENG ; Wenjing LUO ; Xinyi LI ; Jiaojiao BAI ; Liaofang WU ; Ling YU ; Xiaoai FU
Journal of Central South University(Medical Sciences) 2021;46(10):1138-1146
OBJECTIVES:
The measurement of diabetic foot ulcers is important for the success in diabetic foot ulcer management. At present, it lacks the accurate and convenient measurement tools in clinical. In recent years, artificial intelligence technology has demonstrated the potential application value in the field of image segmentation and recognition. This study aims to construct an intelligent measurement model of diabetic foot ulcers based on the deep learning method, and to conduct preliminary verification.
METHODS:
The data of 1 042 diabetic foot ulcers clinical samples were collected. The ulcers and color areas were manually labeled, of which 782 were used as the training data set and 260 as the test data set. The Mask RCNN ulcer tissue color semantic segmentation and RetinaNet scale digital scale target detection were used to build a model. The training data set was input into the model and iterated. The test data set was used to verify the intelligent measurement model.
RESULTS:
This study established an intelligent measurement model of diabetic foot ulcers based on deep learning. The mean average precision@.5 intersection over union (mAP@.5IOU) of the color region segmentation in the training set and the test set were 87.9% and 63.9%, respectively; the mAP@.5IOU of the ruler scale digital detection in the training set and the test set were 96.5% and 83.4%, respectively. Compared with the manual measurement result of the test sample, the average error of the intelligent measurement result was about 3 mm.
CONCLUSIONS
The intelligent measurement model has good accuracy and robustness in measuring the diabetic foot ulcers. Future research can further optimize the model with larger-scale data samples.
Artificial Intelligence
;
Diabetes Mellitus
;
Diabetic Foot
;
Humans
10.Effects of interpregnancy interval on pregnancy outcomes of subsequent pregnancy: a multicenter retrospective study
Juan JUAN ; Huixia YANG ; Yumei WEI ; Geng SONG ; Rina SU ; Xu CHEN ; Qiuhong YANG ; Jianying YAN ; Mei XIAO ; Ying LI ; Shihong CUI ; Yali HU ; Xianlan ZHAO ; Shangrong FAN ; Ling FENG ; Meihua ZHANG ; Yuyan MA ; Zishan YOU ; Haixia MENG ; Haiwei LIU ; Ying ZHU ; Chunfeng WU ; Yan CAI ; Kejia HU ; Hongjuan DING
Chinese Journal of Obstetrics and Gynecology 2021;56(3):161-170
Objective:To explore the effects of interpregnancy interval (IPI) on pregnancy outcomes of subsequent pregnancy.Methods:A multicenter retrospective study was conducted in 21 hospitals in China. Information of age, height, pre-pregnancy weight, IPI, history of diseases, complications of pregnancy, gestational age of delivery, delivery mode, and pregnancy outcomes of the participants were collected by consulting medical records of pregnant women who had two consecutive deliveries in the same hospital during 2011 to 2018. The participants were divided into 4 groups according to IPI:<18 months, 18-23 months, 24-59 months and ≥60 months. According to the WHO′s recommendation, with the IPI of 24-59 months group as a reference, to the effects of IPI on pregnancy outcomes of subsequent pregnancy were analyzed. Stratified analysis was further carried out based on age, history of gestational diabetes mellitus (GDM), macrosomia, and premature delivery, to explore the differences in the effects of IPI on pregnancy outcomes among women with different characteristics.Results:A total of 8 026 women were included in this study. There were 423, 623, 5 512 and 1 468 participants in <18 months group, 18-23 months group, 24-59 months group and ≥60 months group, respectively. (1) The age, pre-pregnancy body mass index (BMI), history of cesarean section, GDM, gestational hypertension and cesarean section delivery rate of <18 months group, 18-23 months group, 24-59 months group and ≥60 months group were gradually increased, and the differences were statistically significant ( P<0.05). (2) After adjusting for potential confounding factors, compared with women in the IPI of 24-59 months group, the risk of premature delivery, premature rupture of membranes, and oligohydramnios were increased by 42% ( OR=1.42, 95% CI: 1.07-1.88, P=0.015), 46% ( OR=1.46, 95% CI: 1.13-1.88, P=0.004), and 64% ( OR=1.64, 95% CI: 1.13-2.38, P=0.009) respectively for women in the IPI≥60 months group. No effects of IPI on other pregnancy outcomes were found in this study ( P>0.05). (3) After stratified by age and adjusted for confounding factors, compared with women in the IPI of 24-59 months group, IPI≥60 months would significantly increase the risk of oligohydramnios for women with advanced age ( OR=2.87, 95% CI: 1.41-5.83, P=0.004); and <18 months could increase the risk of premature rupture of membranes for women under the age of 35 ( OR=1.59, 95% CI: 1.04-2.43, P=0.032). Both the risk of premature rupture of membranes ( OR=1.58, 95% CI: 1.18-2.13, P=0.002) and premature delivery ( OR=1.52, 95% CI: 1.07-2.17, P=0.020) were significantly increased in the IPI≥60 months group. After stratified by history of GDM and adjusted for confounding factors, compared with women in the IPI of 24-59 months group, IPI≥60 months would lead to an increased risk of postpartum hemorrhage for women with a history of GDM ( OR=5.34, 95% CI: 1.45-19.70, P=0.012) and an increased risk of premature rupture of membranes for women without a history of GDM ( OR=1.44, 95% CI: 1.10-1.90, P=0.009). After stratified by history of macrosomia and adjusted for confounding factors, compared with women in the IPI of 24-59 months group, IPI≥60 months could increase the proportion of cesarean section for women with a history of macrosomia ( OR=4.11, 95% CI: 1.18-14.27, P=0.026) and the risk of premature rupture of membranes for women without a history of macrosomia ( OR=1.46, 95% CI: 1.12-1.89, P=0.005). After stratified by history of premature delivery and adjusted for confounding factors, compared with women in the IPI of 24-59 months group, IPI≥60 months would significantly increase the risk of premature rupture of membranes for women without a history of premature delivery ( OR=1.47, 95% CI: 1.13-1.92, P=0.004). Conclusions:Both IPI≥60 months and <18 months would increase the risk of adverse pregnancy outcomes in the subsequent pregnancy. Healthcare education and consultation should be conducted for women of reproductive age to maintain an appropriate IPI when they plan to pregnant again, to reduce the risk of adverse pregnancy outcomes in the subsequent pregnancy.

Result Analysis
Print
Save
E-mail